Mifepristone is a cortisol receptor blocker used to treat Cushing's syndrome, and to terminate pregnancies up to 70 days gestation. Mifepristone is a progestational and glucocorticoid hormone antagonist.
- Mechanism
- Curator reviewed
The anti-progestational activity of mifepristone results from competitive interaction with progesterone at progesterone-receptor sites. Based on studies with various oral doses in several animal species (mouse, rat, rabbit and monkey), the compound inhibits the activity of endogenous or exogenous progesterone. The termination of pregnancy results.
In the treatment of Cushing's syndrome, Mifepristone blocks the binding of cortisol to its receptor. It does not decrease cortisol production but reduces the effects of excess cortisol, such as high blood sugar levels.
- Primary indication
- For the medical termination of intrauterine pregnancy through 49 days' pregnancy.Curator reviewed · 2 structured indications
- Formula / weight
- C29H35NO2 · 429.5937 g/mol (avg)
- First approval
- Canada, 2015 · United States, 2000
- Code names
- RU-38486 · RU-486
- Brand names
Resolves to
VKHAHZOOUSRJNA-GCNJZUOMSA-NSMILES[H][C@@]12CC[C@@](O)(C#CC)[C@@]1(C)C[C@H](C1=CC=C(C=C1)N(C)C)C1=C3CCC(=O)C=C3CC[C@@]21[H]What you can answer from here — as of September 16, 2026
Which drugs share a target with Mifepristone, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account